Skip to main content

Advertisement

SpringerLink
Log in

Pediatric medulloblastoma in the molecular era: what are the surgical implications?

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Pediatric brain tumors are the leading cause of childhood cancer mortality with medulloblastoma (MB) representing the most frequent malignant tumor. Although standardization of therapy resulted in a 2-fold reduction in mortality in patients with MB by 2002, it became clear that further improvements in clinical outcome would require a deeper understanding of the biology of MB. Employing the four main molecular MB subgroups (Wnt, Shh, Group 3 and Group 4), a restratification into clinicogenomic risk categories quantified an unacceptable survival for the high-risk group, urging researchers to focus their efforts towards acquiring a greater biological understanding of these children. Advancing in parallel with the molecular characterization and understanding of pediatric MB is the clinicogenomic correlations giving rise to recommendations for neurosurgical care. While unique observations that distinct radiological patterns can be identified to inform the MB molecular subgroup preoperatively, current neurosurgical practice remains maximal safe surgical resection followed by risk-adapted provision of adjuvant therapy in the context of a clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ellison, D. W., et al. (2011). Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 121(3), 381–396.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bailey, P., Cushings H. (1925). Medulloblastoma cerebelli:a common type of midcerebellar glioma of childhood. Archives of Neurology and Psychiatry, 14, 192–224.

    Article  Google Scholar 

  3. Polkinghorn, W. R., & Tarbell, N. J. (2007). Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nature Clinical Practice. Oncology, 4(5), 295–304.

    Article  CAS  PubMed  Google Scholar 

  4. Ellison, D. (2002). Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathology and Applied Neurobiology, 28(4), 257–282.

    Article  CAS  PubMed  Google Scholar 

  5. Packer, R. J. (2007). Craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. Current Neurology and Neuroscience Reports, 7(2), 130–132.

  6. Packer, R. J., Sutton, L. N., Atkins, T. E., Radcliffe, J., Bunin, G. R., D’Angio, G., Siegel, K. R., & Schut, L. (1989). A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. Journal of Neurosurgery, 70(5), 707–713.

    Article  CAS  PubMed  Google Scholar 

  7. Bull, K. S., et al. (2014). Child-related characteristics predicting subsequent health-related quality of life in 8- to 14-year-old children with and without cerebellar tumors: a prospective longitudinal study. Neurooncol Pract, 1(3), 114–122.

    PubMed  PubMed Central  Google Scholar 

  8. Ellison, D. W. (2010). Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica, 120(3), 305–316.

    Article  PubMed  Google Scholar 

  9. Ris, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., & Boyett, J. M. (2001). Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. Journal of Clinical Oncology, 19(15), 3470–3476.

    Article  CAS  PubMed  Google Scholar 

  10. Palmer, S. L., et al. (2003). Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology, 17(4), 548–555.

    Article  PubMed  Google Scholar 

  11. Palmer, S. L., et al. (2001). Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. Journal of Clinical Oncology, 19(8), 2302–2308.

  12. Mulhern, R. K., Merchant, T. E., Gajjar, A., Reddick, W. E., & Kun, L. E. (2004). Late neurocognitive sequelae in survivors of brain tumours in childhood. The Lancet Oncology, 5(7), 399–408.

    Article  PubMed  Google Scholar 

  13. Yoo, H. J., Kim, H., Park, H. J., Kim, D. S., Ra, Y. S., & Shin, H. Y. (2016). Neurocognitive function and health-related quality of life in pediatric Korean survivors of medulloblastoma. Journal of Korean Medical Science, 31(11), 1726–1734.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Golub, T. R., et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286(5439), 531–537.

    Article  CAS  PubMed  Google Scholar 

  15. Pomeroy, S. L., et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415(6870), 436–442.

    Article  CAS  PubMed  Google Scholar 

  16. Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., Chintagumpala, M., Adesina, A., Ashley, D. M., Kellie, S. J., Taylor, M. D., Curran, T., Gajjar, A., & Gilbertson, R. J. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of Clinical Oncology, 24(12), 1924–1931.

    Article  CAS  PubMed  Google Scholar 

  17. Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S., Caron, H. N., Cloos, J., Mrsić, A., Ylstra, B., Grajkowska, W., Hartmann, W., Pietsch, T., Ellison, D., Clifford, S. C., & Versteeg, R. (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One, 3(8), e3088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., Rutka, J. T., Pfister, S., & Taylor, M. D. (2011). Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology, 29(11), 1408–1414.

    Article  PubMed  Google Scholar 

  19. Cho, Y. J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., Lau, C. C., Olson, J. M., Gilbertson, R. J., Gajjar, A., Delattre, O., Kool, M., Ligon, K., Meyerson, M., Mesirov, J. P., & Pomeroy, S. L. (2011). Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology, 29(11), 1424–1430.

    Article  PubMed  Google Scholar 

  20. Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 123(4), 465–472.

    Article  CAS  PubMed  Google Scholar 

  21. Kool, M., Korshunov, A., Remke, M., Jones, D. T., Schlanstein, M., Northcott, P. A., Cho, Y. J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., Clifford, S. C., Pietsch, T., von Bueren, A., Rutkowski, S., McCabe, M., Collins, V. P., Bäcklund, M. L., Haberler, C., Bourdeaut, F., Delattre, O., Doz, F., Ellison, D. W., Gilbertson, R. J., Pomeroy, S. L., Taylor, M. D., Lichter, P., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathologica, 123(4), 473–484.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Clifford, S. C., Lusher, M. E., Lindsey, J. C., Langdon, J. A., Gilbertson, R. J., Straughton, D., & Ellison, D. W. (2006). Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle, 5(22), 2666–2670.

    Article  CAS  PubMed  Google Scholar 

  23. Ellison, D. W., et al. (2005). Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology, 23(31), 7951–7957.

    Article  CAS  PubMed  Google Scholar 

  24. Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica, 131(6), 803–820.

    Article  PubMed  Google Scholar 

  25. Ramaswamy, V., Remke M, Bouffet E., Bailey S., Clifford SC., et al. (2016). Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 131(6), 821–31.

  26. Johnston, D. L., et al. (2018). Survival following tumor recurrence in children with medulloblastoma. Journal of Pediatric Hematology/Oncology.

  27. Johnston, D. L., Keene, D., Kostova, M., Lafay-Cousin, L., Fryer, C., Scheinemann, K., Carret, A. S., Fleming, A., Percy, V., Afzal, S., Wilson, B., Bowes, L., Zelcer, S., Mpofu, C., Silva, M., Larouche, V., Brossard, J., Strother, D., & Bouffet, E. (2015). Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. Journal of Neuro-Oncology, 124(2), 247–253.

    Article  CAS  PubMed  Google Scholar 

  28. Koschmann, C., et al. (2016). Survival after relapse of medulloblastoma. Journal of Pediatric Hematology/Oncology, 38(4), 269–273.

    Article  CAS  PubMed  Google Scholar 

  29. Sabel, M., Fleischhack, G., Tippelt, S., Gustafsson, G., Doz, F., Kortmann, R., Massimino, M., Navajas, A., von Hoff, K., Rutkowski, S., Warmuth-Metz, M., Clifford, S. C., Pietsch, T., Pizer, B., Lannering, B., & SIOP-E Brain Tumour Group. (2016). Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. Journal of Neuro-Oncology, 129(3), 515–524.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Bowers, D. C., Gargan, L., Weprin, B. E., Mulne, A. F., Elterman, R. D., Munoz, L., Giller, C. A., & Winick, N. J. (2007). Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. Journal of Neurosurgery, 107(1 Suppl), 5–10.

    PubMed  Google Scholar 

  31. Perreault, S., Lober, R. M., Carret, A. S., Zhang, G., Hershon, L., Décarie, J. C., Yeom, K., Vogel, H., Fisher, P. G., & Partap, S. (2013). Relapse patterns in pediatric embryonal central nervous system tumors. Journal of Neuro-Oncology, 115(2), 209–215.

    Article  PubMed  Google Scholar 

  32. Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., Agnihotri, S., Thompson, Y. Y., Kuzan-Fischer, C. M., Farooq, H., Isaev, K., Daniels, C., Cho, B. K., Kim, S. K., Wang, K. C., Lee, J. Y., Grajkowska, W. A., Perek-Polnik, M., Vasiljevic, A., Faure-Conter, C., Jouvet, A., Giannini, C., Nageswara Rao, A. A., Li, K. K. W., Ng, H. K., Eberhart, C. G., Pollack, I. F., Hamilton, R. L., Gillespie, G. Y., Olson, J. M., Leary, S., Weiss, W. A., Lach, B., Chambless, L. B., Thompson, R. C., Cooper, M. K., Vibhakar, R., Hauser, P., van Veelen, M., Kros, J. M., French, P. J., Ra, Y. S., Kumabe, T., López-Aguilar, E., Zitterbart, K., Sterba, J., Finocchiaro, G., Massimino, M., van Meir, E., Osuka, S., Shofuda, T., Klekner, A., Zollo, M., Leonard, J. R., Rubin, J. B., Jabado, N., Albrecht, S., Mora, J., van Meter, T., Jung, S., Moore, A. S., Hallahan, A. R., Chan, J. A., Tirapelli, D. P. C., Carlotti, C. G., Fouladi, M., Pimentel, J., Faria, C. C., Saad, A. G., Massimi, L., Liau, L. M., Wheeler, H., Nakamura, H., Elbabaa, S. K., Perezpeña-Diazconti, M., Chico Ponce de León, F., Robinson, S., Zapotocky, M., Lassaletta, A., Huang, A., Hawkins, C. E., Tabori, U., Bouffet, E., Bartels, U., Dirks, P. B., Rutka, J. T., Bader, G. D., Reimand, J., Goldenberg, A., Ramaswamy, V., & Taylor, M. D. (2017). Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell, 31(6), 737–754 e6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y. J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., Schüller, U., Gururangan, S., McLendon, R., Bigner, D., Fouladi, M., Ligon, K. L., Pomeroy, S. L., Dunn, S., Triscott, J., Jabado, N., Fontebasso, A., Jones, D. T., Kool, M., Karajannis, M. A., Gardner, S. L., Zagzag, D., Nunes, S., Pimentel, J., Mora, J., Lipp, E., Walter, A. W., Ryzhova, M., Zheludkova, O., Kumirova, E., Alshami, J., Croul, S. E., Rutka, J. T., Hawkins, C., Tabori, U., Codispoti, K. E., Packer, R. J., Pfister, S. M., Korshunov, A., & Taylor, M. D. (2013). Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet Oncology, 14(12), 1200–1207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Packer, R. J., Zhou, T., Holmes, E., Vezina, G., & Gajjar, A. (2013). Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro-Oncology, 15(1), 97–103.

    Article  CAS  PubMed  Google Scholar 

  35. Kameda-Smith, M. M., Wang, A., Abdulhadi, N., Voth, R., Sergeant, A., Maharaj, A., Bakhshinyan, D., Adile, A. A., Pai, A. M., Ajani, O., Yarascavitch, B., Alyman, M. C., Duckworth, J., Samaan, M. C., Farrokhyar, F., Singh, S. K., Fleming, A., & Pediatric Brain Tumour Study Group. (2019). Salvage therapy for childhood medulloblastoma: a single center experience. The Canadian Journal of Neurological Sciences, 46(4), 403–414.

    Article  PubMed  Google Scholar 

  36. Robinson, G. W., et al. (2018). Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. The Lancet Oncology, 19(6), 768–784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lafay-Cousin, L., Bouffet, E., Onar-Thomas, A., Billups, C. A., Hawkins, C., Eberhart, C., Horbinski, C., Robinson, G. W., Strother, D. R., Heier, L., Souweidane, M. M., Fouladi, M., Gajjar, A., & Children Oncology Group. (2017). ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age-a report of the Children Oncology Group. Journal of Clinical Oncology,35(15_suppl), 10505–10505.

    Article  Google Scholar 

  38. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier: NCT03434262, SJDWAN: St. Jude Children's Research Hospital Phase 1 study evaluating molecularly-driven doublet therapies for children and young adults with recurrent brain tumours. Available from: https://clinicaltrials.gov/ct2/show/NCT03434262?term;SJDAWN&draw;2&rank;1. Accessed 31 Oct 2019.

  39. Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., Bouffet, E., Fisher, P. G., Partap, S., Vogel, H., Taylor, M. D., Cho, Y. J., & Yeom, K. W. (2014). MRI surrogates for molecular subgroups of medulloblastoma. AJNR. American Journal of Neuroradiology, 35(7), 1263–1269.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Mata-Mbemba, D., Zapotocky, M., Laughlin, S., Taylor, M. D., Ramaswamy, V., & Raybaud, C. (2018). MRI characteristics of primary tumors and metastatic lesions in molecular subgroups of pediatric medulloblastoma: a single-center study. AJNR. American Journal of Neuroradiology, 39(5), 949–955.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lastowska, M., et al. (2018). Medulloblastoma with transitional features between group 3 and group 4 is associated with good prognosis. Journal of Neuro-Oncology, 138(2), 231–240.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Bonner, E. R., et al. (2018). Liquid biopsy for pediatric central nervous system tumors. NPJ Precis Oncol, 2, 29.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Phoenix, T. N., et al. (2016). Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell, 29(4), 508–522.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Moxon-Emre, I., Bouffet, E., Taylor, M. D., Laperriere, N., Scantlebury, N., Law, N., Spiegler, B. J., Malkin, D., Janzen, L., & Mabbott, D. (2014). Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. Journal of Clinical Oncology, 32(17), 1760–1768.

    Article  PubMed  Google Scholar 

  45. ClinicalTrials.gov, A study assessing the feasibility of a surgery and chemotherapy-only in children with Wnt positive medulloblastoma. 2018, ethesda (MD): National Library of Medicine (US).

  46. ClinicalTrials.gov, Reduced craniospinal radiation therapy and chemotherapy in treating younger patients with newly diagnosed WNT-driven medulloblastoma. 2018, National Library of Medicine (US): Bethesda (MD).

  47. ClinicalTrials.gov, A clinical and molecular risk-directed therapy for newly diagnosed medulloblastoma. 2013: Bethesda (MD): National Library of Medicine (US).

  48. ClinicalTrials.gov, International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma. 2014, ethesda (MD): National Library of Medicine (US).

  49. Kameda-Smith, M. M., et al. (2013). Time to diagnosis of paediatric posterior fossa tumours: an 11-year west of Scotland experience 2000-2011. British Journal of Neurosurgery, 27(3), 364–369.

    Article  CAS  PubMed  Google Scholar 

  50. Sergeant, A., et al. (2017). Analysis of surgical and MRI factors associated with cerebellar mutism. Journal of Neuro-Oncology, 133(3), 539–552.

    Article  PubMed  Google Scholar 

  51. Gottardo, N. G., Hansford, J. R., McGlade, J., Alvaro, F., Ashley, D. M., Bailey, S., Baker, D. L., Bourdeaut, F., Cho, Y. J., Clay, M., Clifford, S. C., Cohn, R. J., Cole, C. H., Dallas, P. B., Downie, P., Doz, F., Ellison, D. W., Endersby, R., Fisher, P. G., Hassall, T., Heath, J. A., Hii, H. L., Jones, D. T., Junckerstorff, R., Kellie, S., Kool, M., Kotecha, R. S., Lichter, P., Laughton, S. J., Lee, S., McCowage, G., Northcott, P. A., Olson, J. M., Packer, R. J., Pfister, S. M., Pietsch, T., Pizer, B., Pomeroy, S. L., Remke, M., Robinson, G. W., Rutkowski, S., Schoep, T., Shelat, A. A., Stewart, C. F., Sullivan, M., Taylor, M. D., Wainwright, B., Walwyn, T., Weiss, W. A., Williamson, D., & Gajjar, A. (2014). Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathologica, 127(2), 189–201.

    Article  PubMed  Google Scholar 

  52. ClinicalTrials.gov, A dose exploration study with MK-8628 in participants with selected advanced solid tumors (MK-8628-006). 2018, Bethesda (MD): National Library of Medicine (US).

  53. ClinicalTrials.gov, A dose-finding study of MK-8628, a small molecule inhibitor of the bromodomain and extra-terminal (BET) proteins, in adults with selected advanced solid tumors (MK-8628-003). 2018, National Library of Medicine (US). Bethesda (MD).

  54. Graff, J. N., Higano, C. S., Hahn, N. M., Taylor, M. H., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J., & Sarantopoulos, J. (2016). Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora a kinase inhibitor, with docetaxel in patients with solid tumors. Cancer, 122(16), 2524–2533.

    Article  CAS  PubMed  Google Scholar 

  55. Schoffski, P., et al. (2011). Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. European Journal of Cancer, 47(15), 2256–2264.

    Article  CAS  PubMed  Google Scholar 

  56. Seymour, J. F., et al. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal, 4, e238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Bouffet, E. (2019). Management of high-risk medulloblastoma. Neurochirurgie.

  58. Thompson, E. M., et al. (2016). Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology.

Download references

Acknowledgments

I would like to acknowledge all of the children, families, and international society of researchers who have helped advance the understanding of pediatric MB.

Author information

Authors and Affiliations

  1. Division of Neurosurgery, Department of Surgery, Hamilton General Hospital, McMaster University, 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada

    Michelle M. Kameda-Smith

Authors
  1. Michelle M. Kameda-Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle M. Kameda-Smith.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kameda-Smith, M.M. Pediatric medulloblastoma in the molecular era: what are the surgical implications?. Cancer Metastasis Rev 39, 235–243 (2020). https://doi.org/10.1007/s10555-020-09865-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-020-09865-y

Keywords

Search

Navigation